Additionally, we included further comparisons in the IDH1 mutation status cohort investigating metabolite and pathway alterations in n = 26 IDH1-mut astrocytoma versus n = 29 oligodendroglioma (Figure 1A, comparison IV), n = 7 IDH1-mut glioblastoma versus n = 26 IDH1-mut astrocytoma (Figure 1A, comparison V), n = 7 IDH1-mut glioblastoma versus n = 29 oligodendroglioma (Figure 1A, comparison VI), and n = 9 IDH1-WT astrocytoma versus n = 30 IDH1-WT glioblastoma (Figure 1A, comparison VII). This evidence concerns the gene IDH1 and astrocytoma (excluding glioblastoma).